Lexicon Pharmaceuticals, Inc.

LXRXNASDAQHealthcare● Active

$1.95

+$0.04(+1.85%)

Market Cap$864138898

P/E Ratio—

52W High$2.53

52W Low$0.64

Avg Volume2.6M

Open$1.93

Beta1.07

Free Cash Flow Financials Revenue

Lexicon Pharmaceuticals, Inc. (LXRX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

LXRX · free cash flow · updated Jun 8, 2026

Core FCF metrics

LXRX · FCF · TTM · margin & CAGR

Free cash flow was −$67.9M for FY2025 (fiscal year ending 2025-12-31), up 62.3% year-over-year The FCF margin was -136.2%.

FY2025 Free Cash Flow−$67.9M▲ +62.3% YoY

Trailing 12M (TTM)−$38.8Mtrailing 4 quarters sum

FCF Margin-136.2%−$67.9M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

LXRX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$67.9M(0M)−$67.9M▲ +62.3%-136.2%

FY2024−$178.8M(1M)−$179.8M▼ 10.7%-578.5%

FY2023−$161.9M(0M)−$162.4M▼ 80.1%—

FY2022−$88.9M(1M)−$90.2M▼ 2.2%—

FY2021−$87.0M(1M)−$88.2M▲ +38.3%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

LXRX · P/FCF · FCF yield · FCF per share

Lexicon Pharmaceuticals, Inc. (LXRX) reported negative free cash flow of −$0.07B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

LXRX · cash flow statement · operating / investing / financing

For FY2025, Lexicon Pharmaceuticals, Inc. generated −$67.9M in operating cash flow and spent 0M in capital expenditures, yielding −$67.9M in free cash flow.

Operating Activities

−$67.9M

Cash from core business operations

2025-12-31

Investing Activities

+$113.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$48.5M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$67.9M) − |CapEx| (0M) = FCF (−$67.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

LXRX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Lexicon Pharmaceuticals, Inc.YOU

LXRX

−$67.9M+62.3%-136.2%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Lexicon Pharmaceuticals, Inc. (LXRX) reported free cash flow of −$67.9M for FY2025 (fiscal year ending 2025-12-31), up 62.3% year-over-year. The FCF margin was -136.2%.

Based on available data, Lexicon Pharmaceuticals, Inc. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $183.9M in FY2015.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

LXRX free cash flow · 8 questions

Lexicon Pharmaceuticals, Inc. free cash flow was −$67.9M for FY2025, up 62.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$38.8M.

LXRX free cash flowLXRX FCFLXRX FCF 2025LXRX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Lexicon Pharmaceuticals, Inc. · Lexicon Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026